Clinical trials: Advanced Hematologic Tumors
Advanced Solid Tumors, Hematological Malignancies
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a…
- Trial name
- NCT06224855
- Testing
- DXC006
- Where
- 5 sites in China
- Volunteers
- 280 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Leukemia
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
The primary objective of this study is to estimate the major cytogenetic response (MCyR) rate to Dasatinib in subjects with CP CML, complete and overall hematologic response (CHR and OHR) rate in subjects with AD CML or Ph+ ALL…
- Trial name
- NCT00529763
- Testing
- Dasatinib
- Where
- 14 sites in China
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Refractory Lymphoma
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
- Trial name
- NCT06615193
- Testing
- HDM2005
- Where
- 8 sites in China
- Volunteers
- 111 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody BC8 when given together with fludarabine phosphate and low-dose total-body irradiation followed by donor stem cell transplant and…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00008177
- Testing
- iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult T-cell Leukemia-Lymphoma, Peripheral T-cell Lymphoma
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL
- Trial name
- NCT01169298
- Testing
- Lenalidomide
- Where
- 6 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Celgene
Solid Malignancies, Hematologic Malignancies
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
- Trial name
- NCT06823167
- Testing
- IM-1021
- Where
- 24 sites in United States, Denmark and 2 more
- Volunteers
- 190 people
- Sponsor
- Immunome, Inc.
Hematologic Malignancy
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
- Trial name
- NCT02352558
- Testing
- BBI608, Dexamethasone, Bortezomib
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated…
- Conditions
- Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
- Trial name
- NCT03580655
- Testing
- Avapritinib
- Where
- 32 sites in United States, Austria and 10 more
- Volunteers
- 107 people
- Sponsor
- Blueprint Medicines Corporation
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Advanced Cancer
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT02507544
- Testing
- TRX-818 capsules
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- TaiRx, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003082
- Testing
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arizona
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
AHN-12 Biodistribution in Advanced Leukemia
This study is a single institution phase I study for the treatment of patients with relapsed or refractory leukemia aged 12 years and older using 90Y-AHN-12.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01207076
- Testing
- 90Y-AHN-12
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Metastatic (Stage IV) Colorectal Cancer
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
The present trial is designed to determine whether pre-treatment with PledOx lowers the frequency and severity of side effects from FOLFOX6 administration in patients with metastatic colorectal cancer.
- Trial name
- PLIANT (NCT01619423)
- Testing
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg)
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 186 people
- Sponsor
- Egetis Therapeutics AB (publ)
Advanced Hematologic Malignancies
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after…
- Trial name
- NCT07444268
- Testing
- DSP-5336, [14C]-DSP-5336
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hematologic Malignancy
Home Transfusion for HEME
The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions
- Trial name
- NCT05509439
- Testing
- Home Transfusion Program Components
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Solid Neoplasm, Caregiver
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
This trial studies the frequency of cachexia in ambulatory cancer patients and the psychological burden in patients and their primary caregivers who are referred to an outpatient supportive care clinic.
- Conditions
- Advanced Malignant Solid Neoplasm, Caregiver, Metastatic Malignant Solid Neoplasm, Recurrent Leukemia
- Trial name
- NCT04090619
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Lymphoma
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT00734890
- Testing
- bevacizumab, vandetanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Cancer
Integration of Palliative Care in an Oncology and Hematology Unit
The main goal of this study is to assess retrospectively the integration of Palliative Care in an oncology and hematology unit. The investigators will study the last six month of life on advanced cancer patients and retrieve data…
- Trial name
- NCT04089306
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients Who Have Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic…
- Trial name
- NCT00004047
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo